Goldman Sachs expects Nvidia ’beat and raise,’ lifts price target to $240
DUBLIN - Goldman Sachs International has disclosed its trading position in Avadel Pharmaceuticals PLC (NASDAQ:AVDL) as of October 23, 2025, according to a regulatory filing released Friday.
The investment bank reported holding 197,338 ordinary shares, representing approximately 0.20% of Avadel’s share capital, while maintaining a short position of 66,307 shares, equivalent to 0.06% of the company.
The disclosure, made under Rule 38.5(b) of the Irish Takeover Panel Act, details multiple transactions conducted on October 23, including various share borrowing arrangements, loans, and returns. The transactions did not involve any derivatives or options trading.
Goldman Sachs is serving as an advisor to Avadel Pharmaceuticals in connection with an unspecified takeover matter, as indicated in the filing. The bank is classified as an exempt principal trader without recognized intermediary status, or with recognized intermediary status but not dealing in a client-serving capacity.
The disclosure was submitted to comply with Irish takeover regulations, which require connected parties to report their dealings in relevant securities during takeover periods.
Avadel Pharmaceuticals is a biopharmaceutical company headquartered in Ireland with operations in the United States. The filing was submitted to the Irish Takeover Panel as required by regulatory guidelines.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.